BMS-212122 is a potent microsomal triglyceride transfer protein inhibitor (MTP inhibitor). MS-212122 is significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys. Treatment with BMS-212122 led to rapid reduction in plasma lipid levels, which were accompanied by a significant decrease in lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques compared to baseline and chow diet control groups. BMS-212122-treated mice had increased collagen content, a marker associated with increased stability in human plaques. References: Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013 Mar;227(1):125-9. doi: 10.1016/j.atherosclerosis.2012.12.026. PubMed PMID: 23332773; PubMed Central PMCID: PMC4047651.

纯度：≥98%

CAS：194213-64-4